IDO1 is highly expressed in macrophages of patients in advanced tumour stages of oral squamous cell carcinoma.

Ann-Kristin StruckmeierAnne RadermacherMichael FehrenzTamara BellinDalia AlansaryPhilipp WartenbergUlrich BoehmMathias WagnerAnja SchellerJochen HessJulius MoratinChristian FreudlspergerJürgen HoffmannLorenz ThurnerKlaus RoemerKolja FreierDominik Horn

Published in: Journal of cancer research and clinical oncology (2022)

All in all, IDO1 expressing immune cells, especially macrophages, are more abundant in advanced stages of OSCC and are associated with reduced progression-free survival. Further investigations are needed to explore their role in local and systemic immune response. The IDO1 activity might be a suitable biomarker of metastasis in OSCC patients.

Keyphrases

end stage renal disease
immune response
ejection fraction
newly diagnosed
chronic kidney disease
free survival
prognostic factors
dendritic cells
toll like receptor
patient reported
drug induced